AnalystsBruce D. JacksonBruce D. Jackson's Stock Forecasts
AnalystsBruce D. Jackson
Analyst Ranking
Top 10%
#517 out of 5254 analysts
Average Return
+178.25%
Win Rate
60%9 out of 15
Risk vs Reward
Poor
Good
Bruce D. Jackson's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Exact Sciences CorpEXAS | +2,580.11% | $69.59 | $1,865.09 | 2025-11-04 - 2026-03-24 | Strong Buy |
Unicycive Therapeutics IncUNCY | +78.17% | $3.94 | $7.02 | 2025-09-15 - 2026-04-17 | Buy |
Belite Bio IncBLTE | +56.22% | $105.91 | $165.45 | 2025-10-31 - 2026-04-17 | Strong Buy |
Harvard Bioscience IncHBIO | +36.56% | $4.49 | $6.13 | 2025-09-10 - 2026-04-17 | Buy |
Harvard Bioscience IncHBIO | +29.46% | $4.74 | $6.13 | 2026-03-13 - 2026-04-17 | Buy |
Bruce D. Jackson Analyst Color
Get additional color on Bruce D. Jackson's coverage of popular stocks
Bruce D. Jackson's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Abbott LaboratoriesABT | 1 | Strong Buy | $120.00 | +23.95% | Maintains | 3 days ago |
Unicycive Therapeutics IncUNCY | 2 | Buy | $15.00 | +113.68% | Maintains | 14 days ago |
Humacyte IncHUMA | 3 | Buy | $1.00 | +40.85% | Downgrades | 20 days ago |
Genelux CorpGNLX | 1 | Buy | $20.00 | +616.85% | Maintains | a month ago |
Harvard Bioscience IncHBIO | 3 | Buy | $6.00 | -2.12% | Maintains | a month ago |
Milestone Scientific IncMLSS | 1 | Buy | $1.00 | +254.61% | Maintains | 5 months ago |
Exact Sciences CorpEXAS | 1 | Strong Buy | $75.00 | -95.98% | Maintains | 6 months ago |
Belite Bio IncBLTE | 1 | Strong Buy | $132.00 | -20.22% | Maintains | 6 months ago |
Reviva Pharmaceuticals Holdings IncRVPH | 1 | Buy | $140.00 | +16,370.59% | Maintains | 7 months ago |
Clene IncCLNN | 1 | Strong Buy | $31.00 | +391.28% | Maintains | 7 months ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.